UBS Group’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.09M | Buy |
158,033
+31,361
| +25% | +$219K | ﹤0.01% | 5656 |
|
|
2026
Q1 | $882K | Buy |
126,672
+85,204
| +205% | +$403K | ﹤0.01% | 5651 |
|
|
2025
Q4 | $200K | Sell |
41,468
-18,317
| -31% | -$61.4K | ﹤0.01% | 6579 |
|
|
2025
Q3 | $120K | Sell |
59,785
-120,686
| -67% | -$116K | ﹤0.01% | 6996 |
|
|
2025
Q2 | $108K | Buy |
180,471
+35,682
| +25% | +$18.3K | ﹤0.01% | 7171 |
|
|
2025
Q1 | $39.1K | Sell |
144,789
-70,351
| -33% | -$23.3K | ﹤0.01% | 7765 |
|
|
2024
Q4 | $112K | Buy |
215,140
+88,755
| +70% | +$216K | ﹤0.01% | 6801 |
|
|
2024
Q3 | $409K | Sell |
126,385
-2,415
| -2% | -$7.82K | ﹤0.01% | 5370 |
|
|
2024
Q2 | $386K | Sell |
128,800
-485
| -0.4% | -$1.75K | ﹤0.01% | 5198 |
|
|
2024
Q1 | $601K | Buy |
129,285
+3,555
| +3% | +$17.1K | ﹤0.01% | 5044 |
|
|
2023
Q4 | $521K | Buy |
125,730
+42
| +0% | +$124 | ﹤0.01% | 5071 |
|
|
2023
Q3 | $377K | Buy |
125,688
+26,700
| +27% | +$79.3K | ﹤0.01% | 4877 |
|
|
2023
Q2 | $244K | Buy |
98,988
+97,410
| +6,173% | +$269K | ﹤0.01% | 5355 |
|
|
2023
Q1 | $3.57K | Sell |
1,578
-4,335
| -73% | -$14.9K | ﹤0.01% | 8301 |
|
|
2022
Q4 | $20.6K | Sell |
5,913
-171
| -3% | -$1.5K | ﹤0.01% | 7620 |
|
|
2022
Q3 | $225K | Buy |
6,084
+4,756
| +358% | +$132K | ﹤0.01% | 4986 |
|
|
2022
Q2 | $25K | Hold |
1,328
| – | – | ﹤0.01% | 6612 |
|
|
2022
Q1 | $36K | Sell |
1,328
-1,869
| -58% | -$38.6K | ﹤0.01% | 6825 |
|
|
2021
Q4 | $72K | Sell |
3,197
-1,522
| -32% | -$33.8K | ﹤0.01% | 6597 |
|
|
2021
Q3 | $124K | Buy |
4,719
+98
| +2% | +$2.62K | ﹤0.01% | 5671 |
|
|
2021
Q2 | $148K | Sell |
4,621
-1,925
| -29% | -$66.9K | ﹤0.01% | 5580 |
|
|
2021
Q1 | $230K | Sell |
6,546
-873
| -12% | -$30.5K | ﹤0.01% | 5385 |
|
|
2020
Q4 | $238K | Buy |
7,419
+1,805
| +32% | +$62K | ﹤0.01% | 5135 |
|
|
2020
Q3 | $211K | Sell |
5,614
-2,747
| -33% | -$106K | ﹤0.01% | 4770 |
|
|
2020
Q2 | $374K | Buy |
8,361
+5,318
| +175% | +$225K | ﹤0.01% | 4362 |
|
|
2020
Q1 | $104K | Sell |
3,043
-1,214
| -29% | -$48.9K | ﹤0.01% | 5260 |
|
|
2019
Q4 | $166K | Buy |
+4,257
| New | +$129K | ﹤0.01% | 5718 |
|
Other funds holding RLMD
JT
SCM
VA
SSC
JHC
O
UBS Group's RLMD Position: Q2 2026 in Review
UBS Group increased its Relmada Therapeutics (RLMD) stake by 25% in Q2 2026, buying an estimated $219K and bringing the position to 158,033 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #5656.
UBS Group first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.
- UBS Group held 158,033 shares of Relmada Therapeutics worth $1.09M as of Q2 2026.
- UBS Group bought 31,361 Relmada Therapeutics shares in Q2 2026, an estimated $219K.
- Relmada Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5656 holding.
- UBS Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
- 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.